Drugs / Pneumococcal polysaccharide vaccine
Trials 4
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 31 trial | ||||||
| Phase 3 | NCT05028634 | Nov 2021 → Nov 2023 | relapsing-remitting multiple sclerosis | Celgene Corporation | Completed | No outcome recorded |
| Phase 42 trials | ||||||
| Phase 4 | NCT00919321 | Jun 2009 → Dec 2013 | chronic lymphocytic leukemia/small lymphocytic lymphoma | Tampere University Hospital | Completed | No outcome recorded |
| Phase 4 | NCT00964769 | Apr → May 2005 | — | Ewha Womans University | Completed | No outcome recorded |
| Phase not applicable1 trial | ||||||
| — | NCT00257127 | Feb → Aug 2006 | HIV infectious disease | National Institute of Allergy and Infectious Diseases (NIAID) | Completed | No outcome recorded |
| Comparator or background therapy3 trials | ||||||
| Phase 2 | NCT00788151 Comparator | Sep 2008 → Feb 2010 | Dengue hemorrhagic fever | Sanofi Pasteur, a Sanofi Company | Completed | No outcome recorded |
| Phase 3 | NCT00622843 Comparator | Dec 2002 → Jul 2013 | HIV infectious disease, pneumococcal infection | Henry M. Jackson Foundation for the Advancement of Military Medicine | Completed | No outcome recorded |
| Phase 4 | NCT01402245 Comparator | Jan 2005 → Jun 2010 | streptococcal pneumonia | Helsinki University Central Hospital | Completed | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 7 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Pneumococcal polysaccharide vaccine | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00788151 ↗ |
| Known as | PPV | “Pneumococcal polysaccharide vaccine (PPV)” NCT00919321 ↗ |
| Modality | Vaccine | “Pneumococcal polysaccharide vaccine” NCT00257127 ↗ |
| Route | Intramuscular | “One intramuscular injection” NCT00919321 ↗ |